Co-delivery strategies based on multifunctional nanocarriers for cancer therapy
- PMID: 22380013
- DOI: 10.2174/138920012802849995
Co-delivery strategies based on multifunctional nanocarriers for cancer therapy
Abstract
Chemotherapy is among the most common means for clinicians in the fight against various types of tumors. However, severe toxicity with undesirable toxic effects against normal tissues and cells significantly hinders the applications of these chemotherapeutic agents and leads to multiple complications for patients. Recent developments of nanotechnology-enabled drug delivery platforms allow simultaneous delivery of multiple chemotherapeutic agents to target different metabolic pathways of tumor cells, thus providing new opportunities for higher therapeutic efficacy and lower cytotoxicity. Furthermore, multifunctional nanocarriers can also deliver diagnostic agents, including MRI contrast agents and fluorescent probes, to achieve cancer diagnosis and therapy at the same time. This present review discusses the various aspects of current co-delivery strategies and emphasizes the need for novel designs of biocompatible and non or low toxic nanocarriers. Further studies on potential adverse effects of various nanocarriers are warranted.
Similar articles
-
Nanocarriers for the simultaneous co-delivery of therapeutic genes and anticancer drugs.Curr Pharm Biotechnol. 2012 Jun;13(7):1317-31. doi: 10.2174/138920112800624418. Curr Pharm Biotechnol. 2012. PMID: 22201588 Review.
-
Calcium phosphate nanocarriers for drug delivery to tumors: imaging, therapy and theranostics.Biomater Sci. 2019 Oct 1;7(10):3942-3960. doi: 10.1039/c9bm00831d. Epub 2019 Aug 15. Biomater Sci. 2019. PMID: 31414096 Review.
-
[Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].Yao Xue Xue Bao. 2013 Jul;48(7):1091-8. Yao Xue Xue Bao. 2013. PMID: 24133974 Review. Chinese.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
-
Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer.Curr Drug Deliv. 2016;13(6):830-8. doi: 10.2174/1567201813666151203232852. Curr Drug Deliv. 2016. PMID: 26634791 Review.
Cited by
-
Preparation and Applications of Organo-Silica Hybrid Mesoporous Silica Nanoparticles for the Co-Delivery of Drugs and Nucleic Acids.Nanomaterials (Basel). 2020 Dec 9;10(12):2466. doi: 10.3390/nano10122466. Nanomaterials (Basel). 2020. PMID: 33317099 Free PMC article. Review.
-
Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System.Front Med (Lausanne). 2021 Nov 25;8:750170. doi: 10.3389/fmed.2021.750170. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34901063 Free PMC article. Review.
-
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics.Cancer Metastasis Rev. 2023 Sep;42(3):847-889. doi: 10.1007/s10555-023-10106-1. Epub 2023 May 19. Cancer Metastasis Rev. 2023. PMID: 37204562 Free PMC article. Review.
-
Nanomedicine in the application of uveal melanoma.Int J Ophthalmol. 2016 Aug 18;9(8):1215-25. doi: 10.18240/ijo.2016.08.20. eCollection 2016. Int J Ophthalmol. 2016. PMID: 27588278 Free PMC article. Review.
-
Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.Nanomedicine (Lond). 2014 Feb;9(2):295-312. doi: 10.2217/nnm.13.204. Nanomedicine (Lond). 2014. PMID: 24552562 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources